Why Pfizer's Post-COVID Future Looks Brighter Than Ever
It's been a rough few years to be a Pfizer (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirnaty, racked up $36.8 billion in sales.In the first half of 2025, Comirnaty sales came in at just $945 million. Sales of Paxlovid, an antiviral treatment for COVID-19, fell 60% year over year to $918 million. Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Quelle: MotleyFool
Nachrichten zu Brighter AB
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Brighter AB
Keine Analysen gefunden.